Vaccination in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the immunogenicity of herpes-zoster vaccine (Shingrix) and protection against infection (HZ-REUMA)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506230-71-01

Acronym

HZ_REUMA

Enrollment

Registered

2023-11-06

Start date

2024-12-17

Completion date

Unknown

Last updated

2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory rheumatic diseases (IRD): rheumatoid arthritis (RA), psoriatic arthritis, SLE, spondylarthropathies, systemic vasculitis or systemic sclerosis, vaccination

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Sweden

Outcome results